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A third novel coronavirus leading to severe respiratory 
infection (coronavirus disease 2019, COVID-19) was 
first identified in Wuhan, China in December 2019; as 
of August 2020, there have been 23 million confirmed 
cases with 800,000 deaths worldwide. The clinical spec-
trum resulting from infection with the responsible 
virus, severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2), is broad, ranging from an asymptomatic 
response or development of a mild upper respiratory 
tract infection to critical illness. Initial reports of hospi-
talized patients in Wuhan described a high proportion 
of individuals with atypical pneumonia requiring critical 
care admission with features of acute respiratory distress 
syndrome (ARDS)1,2. The primary pulmonary pathology 
seemed to show not only diffuse alveolar damage but 
also evidence of direct viral cytopathy, implying a direct 
causative role of virus- induced damage in the develop-
ment of ARDS rather than it resulting from a generalized 
inflammatory response.
Initial reports also indicated that rates of acute kid-
ney injury (AKI) were negligible2–7. However, growing 
evidence has demonstrated that AKI is in fact prevalent 
among patients with COVID-19, particularly among 
patients in the intensive care unit (ICU)8–19. The reported 
rates of AKI are extremely variable; however, available 
evidence suggests that it likely affects >20% of hospi-
talized patients and >50% of patients in the ICU8–19. 
Similar to the association of AKI with other forms of 
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community- acquired pneumonia20, AKI is now recog-
nized as a common complication of COVID-19. As 
with AKI from other causes, COVID-19- associated AKI 
(COVID-19 AKI) is associated with adverse outcomes, 
including the development or worsening of comorbid 
disease as well as greater use of health- care resources. 
However, despite considerable advances in our under-
standing and management of other forms of AKI, rela-
tively little is known about the pathogenesis or optimal 
management of COVID-19 AKI.
Given the paucity of knowledge with regard to opti-
mal prevention and treatment strategies for COVID-19 
AKI, the 25th Consensus Conference of the Acute 
Disease Quality Initiative (ADQI) focused on this new 
disease entity. The process was aimed at reviewing the 
current literature relating to COVID-19 AKI, including 
its epidemiology and pathophysiology, and compare 
our current understanding with that of other forms of 
AKI, with the aim of providing recommendations for the 
diagnosis, prevention and treatment of COVID-19 AKI. 
In addition to recommendations for the provision and 
delivery of renal replacement therapy (RRT; also known 
as kidney replacement therapy), we also explored the 
role of other extracorporeal techniques.
Methods
The Conference Chairs of the 25th ADQI consensus 
committee (M.K.N, L.G.F, R.L.M., C.R. and J.A.K.) con-
vened a diverse panel of clinicians and researchers repre-
senting nephrology and critical care from the Americas, 
Europe and Asia to discuss the issues relating to AKI 
associated with COVID-19. The conference was held vir-
tually, over 4 weeks, with weekly virtual consensus meet-
ings from 23 May to 13 June 2020. This consensus 
meeting followed the established ADQI process, and 
used a modified Delphi method to achieve consensus, 
as previously described21.
Conference participants were divided into five work-
groups (Supplementary Box 1), which were tasked with 
addressing the following themes that are central to AKI 
in this patient population: pathophysiology and effects 
of treatments on the kidney; epidemiology and diag-
nosis; prevention and management; RRT, particularly 
under conditions of increased demand (surge); and the 
use of other forms of extracorporeal blood purification 
(EBP) for patients with COVID-19 with or without AKI. 
Members of the workgroups developed core questions, 
performed systematic literature reviews and developed 
a consensus, backed by evidence where possible, to 
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distil the available literature and articulate a research 
agenda to address important unanswered questions. 
Literature searches were performed using the National 
Institutes of Health (NIH) COVID-19 portfolio and 
PubMed. Where possible, delegates were asked to note 
the level of evidence for consensus statements using the 
Oxford Centre for Evidence- based Medicine Levels of 
Evidence22. All of the individual workgroups presented 
their output to conference participants during the four 
videoconference plenary sessions for debate, discussion, 
suggested revisions, and the final product was then 
assessed and aggregated in a videoconference session 
attended by all attendees, who approved the consensus 
recommendations.
Pathophysiology and effects of treatment
Direct pathogenic mechanisms
What direct pathogenic mechanisms have been implicated 
in COVID-19 AKI?
1. Histopathological data are limited, but a wide range of 
pathological findings have been described in patients 
with COVID-19, in keeping with the idea that multiple 
causes of AKI exist, including those commonly found 
in critically ill patients.
2. SARS- CoV-2 might display viral tropism and directly 
affect the kidney.
3. Endothelial dysfunction, coagulopathy and comple-
ment activation are likely important mechanisms for 
AKI in a subset of patients with COVID-19.
4. The role of systemic inflammation and immune dys-
function in the development of COVID-19 AKI is still 
uncertain.
Rationale.  Histopathological data relating to 
COVID-19 AKI are limited, but available evidence sug-
gests that numerous causes of AKI exist in the setting of 
COVID-19 (Fig. 1). A post- mortem study of 26 patients 
who had died with COVID-19 AKI revealed prominent 
acute tubular injury on light microscopy23. In addi-
tion, this and another post- mortem study reported 
the presence of viral particles within both the tubular 
epithelium and podocytes on electron microscopy, 
implying direct infection of the kidney23,24. Collapsing 
glomerulopathy has also been described in patients 
with COVID-19. This morphological variant of focal 
segmental glomerulosclerosis is associated with a range 
of factors, including viral infection, particularly among 
patients of African ancestry, in whom the presence 
of high- risk APOL1 alleles is a genetic risk factor for 
collapsing glomerulopathy, irrespective of cause25–28. 
However, not all reports are in agreement with regard 
to the pathological changes associated with COVID-19. 
For example, a biopsy study of a critically ill patient 
with COVID-19 demonstrated extensive acute tubu-
lar injury, yet real- time PCR on frozen kidney tissue, 
urine and serum were negative for SARS- CoV-2, and 
no evidence of direct viral kidney invasion was found29. 
Similarly, a post mortem study from Germany failed 
to demonstrate morphologically detectable changes in 
the kidney of patients who had died with COVID-19, 
although how many, if any, patients had AKI is unclear30. 
Further autopsy studies have also failed to demonstrate 
the presence of virus in the kidney31. These findings are 
in contrast to another study that documented SARS- 
CoV-2 RNA and protein in precisely defined, microdis-
sected kidney compartments from autopsy specimens. 
Detectable SARS- CoV-2 viral load was demonstrated 
in all kidney compartments examined, with preferential 
targeting of glomerular cells32. In a second study from the 
same group, post- mortem data from patients who had 
COVID-19 respiratory infection demonstrated associa-
tion of SARS- CoV-2 renal tropism with disease severity 
(that is, risk of premature death) and development of 
AKI33. Finally, whether pathological data will emerge to 
support a major role for thrombosis and microangio-
pathy in the kidney in patients with COVID-19 (as has 
been documented in the lung) remains to be seen34,35.
It is unknown but likely that certain genetic traits 
might increase susceptibility to COVID-19 AKI. 
The receptor- binding domain of the SARS- CoV-2 
spike protein gains entry to host cells by binding to 
membrane- bound ACE2 — a protein that is also pres-
ent on kidney tubular epithelial cells and podocytes36,37. 
Of note, limited data suggest that polymorphisms in 
ACE2 might alter the ability of the virus to enter cells. 
As mentioned above, APOL1 genotype might also affect 
disease susceptibility. Although the APOL1 risk alleles 
do not themselves confer a high risk of kidney injury, a 
‘second- hit’, such as that induced by SARS- CoV-2 infec-
tion, may lead to kidney injury38,39. Future investigations 
are needed to clarify these associations.
Endothelial dysfunction — characterized by high 
D-dimer levels and microvascular damage — represents 
a key risk factor for COVID-19- associated coagulopathy. 
Other inherited or acquired pro- thrombotic conditions, 
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Fig. 1 | pathogenesis of CoVID-19 AKI. a,b | The pathogenesis of AKI in patients with 
COVID-19 (COVID-19 AKI) is likely multifactorial, involving both the direct effects of the 
SARS- CoV-2 virus on the kidney and the indirect mechanisms resulting from systemic 
consequences of viral infection or effects of the virus on distant organs including the 
lung, in addition to mechanisms relating to the management of COVID-19. AKI, acute 
kidney injury. Adapted from Acute Disease Quality Initiative 25, www.ADQI.org, CC BY 
2.0 (https://creativecommons.org/licenses/by/2.0/).
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from the breakdown of blood 
clots. D- dimer levels are used 
to identify intravascular 
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such as thrombotic thrombocytopenic purpura and 
atypical haemolytic uraemic syndrome might also con-
tribute to endothelial dysfunction and coagulopathy in 
patients with COVID-19, as might direct viral activa-
tion of the complement system40,41. Importantly, com-
plement activation and thrombotic microangiopathy 
are important mechanisms of kidney injury. However, 
so far, these have not been established as causing AKI in 
COVID-19.
Infection with SARS- CoV-2 is associated with activa-
tion of an inflammatory response that has been termed a 
‘cytokine storm’, which might contribute to the pathogen-
esis of COVID-19- associated multi- organ dysfunction. 
However, what constitutes a cytokine storm remains 
ill- defined42. In other forms of viral respiratory illness 
caused by coronaviruses — severe acute respiratory 
syndrome (SARS; caused by SARS- CoV infection) and 
Middle East respiratory syndrome (MERS; caused by 
MERS- CoV infection) — high levels of pro- inflammatory 
cytokines were associated with more severe respiratory 
disease43–45. However, circulating levels of IL-6 reported 
for patients with COVID-19 are considerably lower than 
those observed in patients treated with chimeric antigen 
receptor T cell therapy; nearly 10,000- fold lower than 
those in patients with cytokine release syndrome, and 
>20,000- fold lower than those in patients with sepsis46,47. 
These comparisons indicate that cytokines are only mod-
erately elevated in COVID-19 and are therefore unlikely 
to be directly pathogenic in most patients. An alterna-
tive explanation may be that these moderately elevated 
cytokines reflect the underlying critical illness, rather than 
representing a ‘storm’ of inflammatory processes per se. 
However, it is important to note that cytokine assays are 
not well standardized, and comparisons between stud-
ies using different assays are often not reliable. Cytokine 
levels, therefore, should be evaluated in larger cohorts of 
patients with COVID-19, as should concomitant analy-
sis of immune cell count and activity. Understanding the 
role of innate and adaptive immune dysfunction in AKI 
patients should be a research priority.
Indirect pathogenic mechanisms
What are the indirect pathogenic mechanisms implicated 
in COVID-19 AKI?
1. Systemic effects of COVID-19 and critical care 
interventions may contribute to AKI.
2. Organ crosstalk is likely an important mechanism for 
AKI in patients with COVID-19.
3. Baseline patient characteristics contribute to AKI, 
acting as modifiers of direct pathogenic mechanisms.
Rationale. In addition to direct pathophysiological 
mechanisms, renal dysfunction in the context of 
COVID-19 might also arise through the systemic effects 
of SARS- CoV-2 infection and critical illness (Fig. 1). For 
example, considerable insensible fluid losses might 
occur through hyperpyrexia and the gastrointestinal 
manifestations of COVID-19, such as diarrhoea, may 
result in volume depletion, an important potential con-
tributor to AKI in other settings. Similarly, critically ill 
patients might be exposed to nephrotoxins as part of 
their clinical care, in particular, antibiotics, which can 
cause tubular injury or acute interstitial nephritis48,49. 
Moreover, individuals who develop secondary infec-
tions (regardless of whether they are bacterial, fungal or 
viral) are at increased risk of secondary sepsis- associated 
AKI50. Patients with severe COVID-19- associated pneu-
monia and/or ARDS are also at a high risk of AKI as 
a complication of mechanical ventilation. Specifically, 
COVID-19- associated ARDS is often treated by increas-
ing positive end- expiratory pressure (PEEP), which leads 
to increased intrathoracic pressure and can ultimately 
result in increased renal venous pressure and reduced 
filtration, which may be further amplified if intra- 
abdominal pressure is elevated (for example, with fluid 
overload)51. In addition, all forms of positive pressure 
ventilation can increase sympathetic tone, leading to sec-
ondary activation of the renin–angiotensin system52,53. 
In the setting of ARDS after shock resolution, patients are 
often managed with a restrictive fluid strategy. However, 
in the setting of COVID-19, patients may initially pres-
ent with relative volume depletion due to fever and 
gastrointestinal losses, and therefore careful attention 
to volume status is needed to avoid hypovolaemia.
Organ crosstalk describes the complex and mutual 
biological communication between distant organs 
mediated by signalling factors, including cytokines 
and growth factors, as well as the release of damage- 
associated molecular patterns (DAMPs) from injured tis-
sue. Such crosstalk has also been suggested to mediate 
AKI in the setting of ARDS54,55.For example, lung injury 
in patients with COVID-19 can be severe and abrupt 
and lead to the release of not only DAMPs but also 
cytokines, chemokines and vasoactive substances that 
may continue to AKI. Tissues other than the lung might 
also serve as sources of DAMPs; for example, rhabdo-
myolysis in the setting of COVID-19 would result in the 
release of myoglobin from muscle56.
Available evidence suggests that older age, chronic 
kidney disease (CKD), and the presence of other comor-
bidities (for example, diabetes mellitus, hypertension, 
obesity, heart failure and chronic obstructive pulmo-
nary disease) are associated with worse outcomes and 
also represent risk factors for the development of AKI 
in patients with COVID-19. These clinical features are 
characterized by low- grade inflammation and increased 
immune senescence, although how these impact the 
kidney in the setting of COVID-19 is unknown57.
Recovery mechanisms
What are the potential mechanisms for recovery from 
COVID-19 AKI?
1. Whether recovery from COVID-19 AKI differs from 
other forms of AKI is unknown. More research is 
needed to better understand the direct impact of the 
SARS CoV-2 virus on long- term renal fibrosis and 
recovery.
Rationale. Pulmonary fibrosis in patients following 
recovery from COVID-19 has been reported58. Although 
we do not yet know whether kidney fibrosis occurs in 
patients who recover from COVID-19 AKI, the develop-
ment of fibrosis and progression to CKD among patients 
who recover from other forms of AKI suggest that this 
Cytokine storm
Uncontrolled cytokine release 
into the systemic circulation, 
often associated with defects 
in immune regulation, either 
genetic or acquired such as in 
macrophage activation 
syndrome.
Positive end- expiratory 
pressure
(PEEP). Pressure applied to a 
ventilatory circuit to prevent 
airway collapse and to increase 
mean airway pressure, a 
determinant of oxygenation.
Damage- associated 
molecular patterns
(DAMPs). Endogenous 
molecules that can precipitate 
inflammation often by 
signalling through specific 
receptors such as Toll- like 
receptors. DAMPs frequently 
arise from injured or dying cells 
(e.g. myoglobin, HMgB1, uric 
acid).
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scenario is likely. Moreover, the loss of functioning 
nephrons following injury might enhance the develop-
ment of renal fibrosis. We recommend that patients with 
COVID-19 AKI be followed over a period of 2–3 months 
post- discharge, depending on the severity and acute 
needs of the patient, to evaluate kidney recovery59.
Epidemiology and diagnosis
Incidence and diagnosis
What are the rates of COVID-19 AKI, and how should it 
be diagnosed?
Recommendations. 
1. Timing of AKI with symptom onset, hospitalization, 
confirmation of infection, disease severity and level of 
care should be characterized for appropriate clinical 
management (not graded).
2. We recommend use of the Kidney Disease: Improving 
Global Outcomes (KDIGO) consensus definition for 
AKI, including serum creatinine (SCr) level and urine 
output, in clinical practice (evidence level: 1A).
3. We suggest using kidney- specific tests along with 
measures of kidney function to characterize clinical 
presentations, course and outcomes of AKI (evidence 
level: 2B).
Rationale. Rates of reported AKI vary considerably 
between studies, with higher rates reported in countries 
outside of China (TABlE 1). Patients with COVID-19 may 
present with AKI or develop it during the course of their 
hospitalization. Those requiring admission to the ICU 
have a higher rate of AKI than those hospitalized on 
the wards. Of note, many published reports of patients 
with COVID-19 do not include definitions or staging 
of AKI, or information on renal recovery or follow up. 
The distinction between de novo AKI and AKI super-
imposed on pre- existing CKD is also rarely made. In 
addition, reported hospital admission rates of patients 
with COVID-19 varies between and within countries, 
reflecting different national and regional health- care sys-
tems, policies for hospitalization and for assigning levels 
of care (e.g. ICU admission). These factors all complicate 
comparisons of AKI rates based solely on the number 
of hospitalized patients. This variation is exemplified by 
data from the UK, where initial rates of AKI in April 2020 
(as defined by need for RRT) were reported to be 20% in 
hospitalized patients with a reported mortality of over 
80%, whereas data from July 2020 showed an incidence of 
27% but an observed mortality of 57%60 (TABlE 1). Rather 
than reflecting an improvement in AKI outcomes, this 
variation reflects incomplete follow- up whereby more 
recent data from patients with shorter lengths of stay is 
not representative of the overall cohort. Such confound-
ers should be considered when examining crude rates of 
AKI and the need for RRT.
We recommend using KDIGO criteria for defining 
and reporting AKI61 to enable between- study compari-
son and because increased recognition of AKI through 
use of these criteria can improve survival61,62. Using 
these criteria, the epidemiology of COVID-19 AKI 
(TABlE 1) looks fairly similar to that of other forms of 
community- acquired pneumonia20. The lack of SCr 
measurements prior to hospital admission often impedes 
the ability to identify underlying CKD and creates chal-
lenges for the reliable detection and staging of AKI, 
emphasizing the need to define the baseline SCr clearly. 
One study in which baseline SCr measurements were 
available reported that 35% of patients with COVID-19 
AKI had underlying CKD17. To improve understanding 
of the epidemiology and temporal nature of COVID-19 
AKI, investigators must correlate the timing of AKI with 
COVID-19 symptom onset, hospitalization, confirma-
tion of SARS- CoV-2 infection, disease severity and level 
of care when reporting AKI rates.
Although urine volume is reported infrequently, 
two- thirds of patients have low urinary sodium concen-
trations at the time of AKI, and the majority are oliguric 
at RRT initiation16,17. Urinalysis and biomarkers of AKI 
are frequently abnormal in patients with COVID-19 and 
could be used to characterize AKI in these patients5,8,16,17. 
For example, one study reported that among the 32% 
of patients hospitalized with COVID-19 for whom uri-
nalysis was available, 42.1% had significant proteinuria, 
with leukocyturia and haematuria in 36.5% and 40.9%, 
respectively16. Similarly, a study of urinalysis data from 
442 hospitalized Chinese patients with COVID-19, 
proteinuria was present in 43.9% (with 30% having ≥2+ 
on dipstick) with significant haematuria demonstrated 
in 11.3%5. Examination of urinary sediment can be an 
effective tool in clinical scenarios in which more than 
one possible cause of AKI may exist that could affect 
medical management, for example, to distinguish 
acute tubular necrosis from pre- renal AKI, although 
special precautions may be needed when handling 
biospecimens from patients with COVID-19 (rEF.63). 
The role of urinary markers for injury or stress in the 
diagnosis of COVID-19 AKI remains unclear. Patients 
with COVID-19 AKI and high levels of tissue inhibi-
tor of metalloproteinases-2 and insulin- like growth 
factor- binding protein-7 [TIMP-2] × [IGFBP-7] were 
more likely to progress to RRT than patients with AKI 
but with low [TIMP-2] × [IGFBP-7]64. Elevated urinary 
alpha1- microglobulin in hospitalized patients was associ-
ated with the subsequent development of AKI64. Patients 
with COVID-19 AKI have also been reported to have 
higher levels of systemic markers of inflammation, par-
ticularly ferritin, C- reactive protein, procalcitonin and 
lactate dehydrogenase, than patients with COVID-19 
and normal kidney function17.
Risk factors
What are the risk factors for AKI with COVID-19 infection?
Recommendations. 
1. We suggest that patients be stratified for risk of AKI 
based on their comorbidities and demographics. 
Information about baseline CKD, comorbidities, and 
demographics should be obtained to define risk profiles 
of COVID-19 AKI (Box 1) (evidence level: 2C).
2. Risk factors for community and hospital- acquired AKI, 
severity of illness, process of care, along with the thresh-
old for admission to the hospital and the ICU should be 
considered when evaluating patients with COVID-19 
(not graded).
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Rationale. Risk stratification is important to tailor 
monitoring and initiate prevention and/or early treat-
ment strategies for patients who will benefit the most 
from intervention. Data from China and the USA 
suggest that male sex, older age, Black race, diabetes 
mellitus, CKD, hypertension, cardiovascular disease, 
congestive heart failure and higher body mass index are 
associated with COVID-19 AKI8,16,17. Among patients 
with COVID-19, those with AKI are more likely to 
require vasopressors as well as mechanical ventilation16,17. 
No data exist on criteria for ICU admission, or the 
association between medications and procedures 
(e.g. surgeries, contrast medium administration) and 
COVID-19 AKI.
AKI rates vary considerably between geographic 
regions and between different health systems. Data 
from China suggest that AKI is less common among 
patients in China2–6,8–12,65,66 than among patients in the 
Table 1 | rates of AKI and rrT in hospitalized patients with CoVID-19
Study 
population
N ICU 
(%)
Comorbidities AKI 
definition
AKI (%) rrT (%) Mortality in 
patients with 
AKI (%)
ref
China
Wuhan 116 0% HTN: 37%; DM:16%; CKD: 4% KDIGO 0% 4% NR 3
Wuhan 99 23% CVD: 40%; DM: 12% SCr 
>1.3 mg/dl
3% 9%; 39% in 
ICU
NR 4
Wuhan 138 26% HTN: 31%; DM: 10%; CKD: 3% KDIGO 4%; 8% in ICU 2%; 6 % in 
ICU
NR 2
Wuhan 333 17% HTN: 32%; DM: 23% KDIGO 11% (46% stage1; 
23% stage 2; 31% 
stage 3); 43% in ICU
3% in ICU 57%; 25% in 
stage 1; 75%  
stage 2; 90%; 
stage 3
8
Wuhan 701 10% HTN: 33%: DM:14%; CKD: 2% KDIGO 5% (2% stage 1; 1% 
stage 2; 2% stage 3)
NR 34% in patients 
with AKI on 
admission
5
Wuhan 41 32% HTN: 15%; CVD: 15%; DM: 20% KDIGO 7%; 23% in ICU 7%; 23% in 
ICU
NR 65
Wuhan 274 - HTN: 34%; CVD: 8%; DM: 17% KDIGO 11% 1% NR 9
Wuhan 191 26% HTN: 30%: DM: 19%; CKD: 1% KDIGO 15% 5% NR 10
Wuhan 52 100% CVD: 23%; DM: 17% KDIGO 29% 17% NR 11
Wuhan 102 18% HTN: 28%; CVD: 10%;  
DM: 11%; CKD: 4%
NR 20% 6% NR 12
30 regions 1,099 5% HTN; 15%; DM: 7%; CKD: 0.7% KDIGO 0.5%; 6% in ICU 0.8%; 12% 
in ICU
NR 6
Jiangsu 80 0 CVD: 31%; CKD: 1% NR 3% 1% NR 7
USA
Washington 21 100% CKD: 48%; ESRD: 10% Need for 
RRT
19% NR NR 13
New York 5700 22% HTN 56%; CVD:18%;  
CKD: 5%; ESRD: 4%
KDIGO 24% 4% NR 14
New York 1000 24% HTN: 60%; CVD: 23%;  
DM: 37%; CKD: 14%
Defined by 
clinic notes 
in EHR
34%; 78% in ICU 14%; 35% 
in ICU
NR 15
New York 257 100% HTN: 63%; CVD: 19%;  
DM: 36%; CKD: 14%
NR NR 31% NR 68
New York 5449 26% HTN: 56%; CVD: 18%;  
DM: 33%
KDIGO 37% (47% Stage 1; 
22 % Stage 2; 31% 
Stage 3); 76% in ICU
23% in ICU 35% 16
Louisiana 575 30% HTN: 72%; DM: 48%;  
CKD: 29%
KDIGO 28%; 61% in ICU 15%; 73% 
in ICU
50%; 72% in 
patients on RRT
17
Multicentre 2215 100% HTN: 60%; CVD: 22%;  
DM: 39%; CKD: 13%: ESRD: 3%
KDIGO 
Stage 2 
and 3
43% 20% NR 19
Europe
United 
Kingdom
2,743 (April 2020) 
10,547 (July 2020)
100% CVD: 0.7%: ESRD: 2% Need for 
RRT
NR 20% (April) 
27% (July)
80% (April) 
57% (July)
18
AKI, acute kidney injury; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; EHR, electronic health record; HTN, hypertension; 
ICNARC, Intensive Care National Audit & Research Center; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; RRT, renal replacement 
therapy; SCr, serum creatinine; NR, not reported.
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USA13,14,16,17,19,67,68 and Europe60. This difference may 
be attributed to differences in the patient population 
studies; for example, patients in the Chinese studies 
had fewer comorbidities and were admitted to hospi-
tal with less severe respiratory disease or ARDS than 
patients in other cohorts (TABlE 1). To date, there are no 
data on risk factors for COVID-19 AKI between dif-
ferent hospital settings (for example, academic versus 
community hospitals, or rural versus urban hospitals) 
and although rapid surges in hospital admissions related 
to COVID-19 have been reported in New York, USA 
and China, no multicentre studies have considered 
the impact of hospital strain and resource allocation on the 
risk of AKI.
Clinical course and prognosis
What is the clinical course and prognosis of COVID-19 AKI?
Recommendations. 
1. We recommend that patients be monitored for AKI 
throughout their hospital course and be followed for 
recovery post- discharge (evidence level: 1B).
2. When feasible, renal histology, particularly in cases of 
heavy proteinuria, may help to differentiate potential 
causes of AKI (not graded).
Rationale. Geographic and regional differences in the 
course and outcomes of COVID-19 AKI are recognized. 
However, the influence of resource limitations has not 
been well described. In general, patients with COVID-19 
who develop AKI are more likely to be admitted to the 
ICU and to require mechanical ventilation and vaso-
pressors than patients who do not develop AKI. Few 
studies have explored the temporal relationship between 
the onset or severity of SARS- CoV-2 infection and the 
development of AKI. Although one study reported that 
approximately one- third of patients presented either 
with AKI or developed AKI within 24 h of presentation16, 
another study reported a considerable delay in the man-
ifestation of AKI in patients with COVID-19 (median of 
15 days from presentation)10, which potentially differ-
entiates COVID-19 AKI from AKI caused by other sys-
temic infections. A temporal association of COVID-19 
AKI with intubation has been observed; however, the 
extent to which these temporal relationships are related 
to disease progression, organ crosstalk or associated with 
interventions such as peri- intubation haemodynamic 
changes is unclear16,17.
Available reports indicate that rhabdomyolysis 
occurs in 7–20% of patients with evidence of COVID-19 
AKI8,17. Hyperkalaemia has been noted in 23% of 
patients with COVID-19 AKI, and is often associated 
with metabolic acidosis17,69. As mentioned earlier, a 
large proportion of patients, particularly those who 
were critically ill and/or had overt AKI, had evidence 
of haematuria and proteinuria8,16,17,64. Histological eval-
uation from autopsy series and biopsy case reports of 
patients with heavy proteinuria have identified several 
different patterns of injury — collapsing glomerulopa-
thy, proximal tubule injury and microangiopathy with 
microthrombi — that have the potential to inform sub-
sequent management23–25,27,32,70. Of note, various factors 
specific to COVID-19, including the use of mechanical 
ventilation, anticoagulation requirements, and logis-
tical complexities given the risk of viral transmission, 
make renal biopsies difficult to obtain in patients with 
suspected AKI.
The duration of COVID-19 AKI is poorly under-
stood, and only one study has reported recovery of kid-
ney function8. The mortality of COVID-19 AKI has been 
reported to be between 35% and 80% with rates as high 
as 75–90% among patients requiring RRT, serving as an 
independent risk factor for all- cause in- hospital death in 
patients with COVID-19 (rEFs5,8,16,17,60).
Research recommendations
1. Future studies should consider the impact of geo-
graphical variation, differences in health- care 
systems, the influence of hospital capacity, the pre-
paredness of health- care systems and social deter-
minants on the epidemiology of COVID-19 AKI, 
including analysis of how these factors influence risk 
factors, management of disease and outcomes.
2. Future studies should incorporate information about 
the proportion of different comorbidities in patients 
with and without AKI, including potential risk fac-
tors for the development of COVID-19 AKI before 
and after hospital admission.
3. Future studies should determine different phenotypes 
of COVID-19 AKI based on clinical presentation at 
diagnosis, patterns of injury, duration and course of 
AKI, and progression to CKD.
4. The severity of COVID-19 disease at AKI diagno-
sis and the interventions that have been used for the 
management of the individual should be reported 
when describing COVID-19 AKI.
5. The relationship between markers of systemic dis-
ease (for example, ferritin, D- dimers, non- respiratory 
organ failure) and the severity of pulmonary disease to 
the development, course and outcomes of COVID-19 
Box 1 | potential risk Factors for CoVID-19 AKI
Demographic risk factors
•	Older age
•	Diabetes mellitus
•	Hypertension
•	Cardiovascular disease or congestive 
heart failure
•	High body mass index
•	Chronic kidney disease
•	Genetic risk factors (e.g. APOL1 
genotype; ACE2 polymorphisms)
•	immunosuppressed state
•	smoking history
risk factors for AKI at admission
•	severity of COviD-19
•	Degree of viraemia
•	respiratory status
•	Non- respiratory organ involvement,  
e.g. diarrhoea
•	Leukocytosis
•	Lymphopaenia
•	elevated markers of inflammation,  
e.g. ferritin, C- reactive protein, 
D-dimers
•	Hypovolaemia/Dehydration
•	rhabdomyolysis
•	Medication exposure, e.g. angiotensin- 
converting- enzyme (aCe) inhibitors  
and/or angiotensin- receptor blockers 
(arBs), statins, nonsteroidal 
anti-inflammatory drugs (NsaiDs)
risk factors for AKI during 
hospitalization
•	Nephrotoxins (medications, contrast 
exposure)
•	vasopressors
•	ventilation, high positive end- expiratory 
pressure
•	Fluid dynamics (fluid overload or 
hypovolaemia)
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AKI warrants further study. Risk factors for develop-
ing severe AKI (stage 3 AKI or requiring RRT initi-
ation) need to be explored to identify approaches to 
prevent AKI.
6. The mechanism, timing and clinical implications 
of traditional markers of AKI (proteinuria and 
haematuria) as well as novel biomarkers for the diag-
nosis and prognosis of AKI need to be studied and 
correlated with markers of systemic disease.
7. Kidney recovery and mortality should be assessed 
at ICU and hospital discharge. Post- hospitalization 
outcomes and long- term renal recovery data should 
be evaluated across different countries.
Prevention and management of AKI
Standard- of- care strategies
What standard- of- care strategies are applicable to the 
prevention and management of AKI in patients with 
COVID-19?
Recommendations. 
1. Strategies based on KDIGO and other relevant guide-
lines are appropriate for risk- and stage- based preven-
tion and management of COVID-19 AKI (TABlE 2) 
(not graded).
2. We recommend individualized fluid and haemody-
namic management based on dynamic assessment 
of cardiovascular status for critically ill patients with 
COVID-19 (evidence level: 1B).
3. We recommend using balanced crystalloids as initial 
management for the expansion of intravascular volume 
in patients at risk of AKI or with AKI unless a specific 
indication exists for the use of other fluids (evidence 
level: 1A).
4. We recommend limiting nephrotoxic drug exposure 
where possible and with careful monitoring when 
nephrotoxins are required (evidence level: 1B).
Rationale. No specific evidence is available to suggest 
that COVID-19 AKI should be managed differently 
from other causes of AKI in critically ill patients, and 
indeed few recommendations for AKI are aetiology 
specific. Thus, most of the measures recommended 
by KDIGO and other relevant guidelines are appro-
priate for patients with COVID-19 (rEFs61,71) (TABlE 2  
and Fig. 2).
Hypovolaemia is common in early COVID-19 and 
hence individualized fluid management is critical72. 
A randomized clinical trial (RCT) demonstrated that 
fluid and vasopressor resuscitation based on dynamic 
haemodynamic assessment may reduce the risk of 
AKI and respiratory failure in patients with septic 
shock73. We suggest that a similar strategy may be valu-
able in patients with COVID-19 to reduce the risk of 
COVID-19 AKI.
Since the publication of the KDIGO guidelines for 
AKI in 2012 (rEF.61), more evidence has emerged regard-
ing the importance of the composition of crystalloids 
used for volume expansion74–77. The Isotonic Solutions 
and Major Adverse Renal Events Trial (SMART) demon-
strated that compared with saline, use of balanced crys-
talloids decreased the composite outcome of death, new 
RRT, or persistent kidney dysfunction among critically 
ill adults, with the largest effect observed among patients 
with sepsis78. This beneficial effect was replicated in 
non- critically ill patients and in the perioperative 
setting75,76. However, three systematic reviews of studies 
in adults and children did not demonstrate reduced rates 
of AKI or mortality with balanced crystalloids compared 
with saline in pooled analyses79–81. Given the possible 
harm caused by the use of 0.9% saline we recommend 
using balanced fluids, unless there is an indication for 
other types of fluid (e.g. saline 0.9% for hypochloraemic 
hypovolaemia).
Several strategies have also emerged for the preven-
tion or mitigation of drug- associated AKI, the most 
important one being drug stewardship. Single- and 
multi- centre collaborative studies that have used elec-
tronic health records to identify children exposed to 
≥3 nephrotoxic drugs led to a sustained decrease in 
AKI40,82,83. The use of multiple nephrotoxic medications 
is common among patients with COVID-19 who are at 
a high risk of AKI, so drug stewardship is particularly 
important.
COVID-19- specific strategies
What COVID-19- specific interventions are potentially 
beneficial for the prevention and management of AKI?
Recommendations. 
1. Patients with COVID-19 AKI should be treated using 
the KDIGO- based standard of care (not graded).
2. We suggest that ventilator strategies in patients with 
COVID-19 be selected to reduce the risk of AKI when 
possible (evidence level: 2C).
Rationale. In the absence of a specific treatment for 
COVID-19 AKI, management should follow current 
consensus recommendations for AKI (TABlE 2). The role 
of antivirals, immunomodulatory agents (including cor-
ticosteroids), renin–angiotensin inhibitors, statins and 
anticoagulants in the prevention and/or mitigation of 
AKI remains unknown2,83–88 (TABlE 2). As for patients 
with other forms of ARDS, lung- protective mechani-
cal ventilation strategies are recommended for patients 
with severe COVID-19. However, for the reasons noted 
above, excessive PEEP might result in high systemic 
venous pressure and a reduction in kidney perfusion 
and glomerular filtration54. Therefore, individualization 
of PEEP with consideration of its risks and benefits is 
recommended; the optimal ventilation strategy depends 
on the degree and extent of airspace disease and com-
pliance of the lungs89. Existing data suggest that prone 
positioning in respiratory failure does not impact the 
risk of AKI90.
Of note, the Adaptive Covid-19 Treatment Trial 
(ACTT-1) reported that compared with placebo, treat-
ment with remdesivir shortened recovery time among 
adult patients hospitalized with COVID-19 and evidence 
of lower respiratory tract infection84. In addition, the 
Recovery trial demonstrated that use of dexamethasone 
reduced 28- day mortality among hospitalized patients 
with COVID-19, with the strongest effect seen in 
patients receiving either invasive mechanical ventilation 
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or oxygen therapy alone at randomization84,91. Neither of 
these trials reported effects on renal function although 
more details may be available in time.
AKI- specific treatment considerations
What interventions in the management of COVID-19 
should be modified in patients with AKI?
Table 2 | potential management strategies for CoVID-19 AKI
Therapy rationale recommendation
Standard measures
Standard measures based on 
AKI risk and stage
Prevention and management depend on the risk and stage 
of AKI
Strategies based on KDIGO and other relevant 
guidelines are appropriate for risk- and stage- based 
prevention and management of COVID-19 AKI 
(ungraded)
Measurement of kidney 
function
The measurement of kidney function is necessary for precise 
clinical assessment of risk and stage of AKI. Serum creatinine 
and urine output are the current gold standards for the 
evaluation of kidney function, although neither is kidney 
specific or sensitive for detection of early kidney injury
We recommend monitoring kidney function using 
a minimum serum creatinine and urine output with 
careful consideration of the limitations of both 
(evidence level: 1B)
Haemodynamic optimization Hypovolaemia, hypotension, and vasoplegia may occur in 
patients with COVID-19. Fluid and vasopressor resuscitation 
using dynamic assessment of cardiovascular status may 
reduce the risk of renal injury and respiratory failure
We recommend individualized fluid and 
haemodynamic management based on dynamic 
assessment of cardiovascular status (evidence 
level: 1B)
Fluid management The composition of crystalloids for volume expansion is 
important. Individual trials in non- COVID patients have 
shown reduced risk of AKI with use of balanced fluids for 
initial volume expansion, especially in sepsis
We recommend using balanced crystalloids as initial 
management for expansion of intravascular volume 
in patients at risk of or with COVID-19 AKI unless an 
indication for other fluids exists (evidence level: 1A)
Glucose management Insulin resistance and a hypercatabolic state are common in 
COVID-19 and contribute to hyperglycaemia
We suggest monitoring for hyperglycaemia and use 
of intensive glucose- lowering strategies in high- risk 
patients (evidence level: 2C)
Nephrotoxin management Nephrotoxins are frequently prescribed in patients with 
COVID-19. The risks and benefits of these medications 
and their alternatives need to be closely and frequently 
assessed. This includes assessment of NSAID use
We recommend limiting nephrotoxic drug exposure 
where possible and with careful monitoring when 
nephrotoxins are required (evidence level: 1B)
Use of contrast media Some studies have challenged the relevance of contrast 
media toxicity in critically ill patients; furthermore, sodium 
bicarbonate and N- acetylcysteine have not been shown to 
prevent contrast- media- associated AKI
We recommend optimization of intravascular 
volume status as the only specific intervention to 
prevent contrast- media- associated AKI (evidence 
level: 1A)
Experimental strategies
Antivirals Some evidence suggests that direct viral infiltration of 
tubular cells and podocytes has an impact on tubule 
function and glomerular filtration
Evidence that antivirals may reduce the risk  
of COVID-19 AKI is indirect and limited
Immunomodulatory agents 
(e.g. hydroxychloroquine, 
corticosteroids, tocilizumab, 
sarilumab, anakinra, imatinib, 
dasatinib, ciclosporin, 
immunoglobulins, baricitinib)
SARS- CoV-2 infection can induce the release of IL-1, 
IL-6, TNF and other cytokines, as well as secondary HLH. 
Immunomodulatory agents have the potential to attenuate 
cytokine production or block cytokine- receptor activation 
and inhibit autophagy and lysosomal activity to modulate 
inflammation in host cells
Existing data on immunomodulation in COVID-19 
do not show an impact on the development or 
progression of AKI
Systemic anticoagulation Thrombi in the renal microcirculation may contribute to the 
development of AKI
No data are available to show that anticoagulation 
strategies reduce the risk of AKI or mitigate AKI 
progression. Systemic anticoagulation may be 
needed to maintain filter patency during RRT
Statins Statins inhibit the production of pro- inflammatory 
cytokines (e.g. TNF, IL-10, IL-6 and IL-8) and the activation 
and proliferation of T cells, potentially leading to 
immunomodulation
No data are available to show that statins reduce the 
risk of AKI or mitigate progression
ACE- I and/or ARBs ACE- I and ARBs increase ACE2 levels and may rescue 
cellular ACE2 activity
The impact of RAAS inhibitors on the development 
or prevention of COVID-19 AKI is uncertain
NSAIDs Anti- inflammatory properties Effect unknown
Recombinant ACE2 Potential to neutralize the SARS- CoV-2 and rescue cellular 
ACE2 activity
Under investigation
Serine inhibitors Blockage of transmembrane protease serine 2 activity and 
prevention of viral infiltration
Under investigation
ACE, angiotensin- converting- enzyme inhibitor; ACE2, angiotensin converting enzyme 2; AKI, acute kidney injury; ARB, angiotensin- receptor binder;  
HLH, haemophagocytic lymphohistiocytosis; JAK, Janus kinase; KDIGO; Kidney Disease: Improving Global Outcomes; RAAS, renin–angiotensin–aldosterone 
system; RRT, renal replacement therapy.
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Recommendations. 
1. We recommend that the altered pharmacokinetics 
and renal effects of COVID-19- specific therapeutics 
are considered when prescribing and adjusting dosage 
(evidence level: 1C).
2. COVID-19 is associated with malnutrition; how-
ever, whether patients with COVID-19 AKI have 
specific nutritional requirements is unclear (not 
graded).
Rationale. Several drugs or their metabolites that have 
been proposed for use in patients with COVID-19 are 
excreted and/or metabolized via the kidneys and require 
dose adjustment or are contraindicated in patients with 
impaired kidney function or during RRT. In addi-
tion, other conventional therapies, such as antibiotics 
or anticoagulants, have altered pharmacokinetics in 
patients with AKI (Supplementary Table 1). Patients 
with COVID-19 are at risk of malnutrition due to vari-
ous factors such as prolonged immobilization, catabolic 
changes and reduced food intake53,92; however, no dedi-
cated studies on nutritional management in patients with 
COVID-19 AKI exist. Therefore, current consensus rec-
ommendations for the nutritional management of criti-
cally ill patients should be followed61,93–95. Protein intake 
should be gradually increased to 1.3–1.5 g/kg per day in 
patients with AKI who are not on RRT; 1.0–1.5 g/kg per 
day for patients on intermittent RRT and up to 1.7 g/kg 
per day for patients on continuous RRT (CRRT). Early 
enteral feeding is preferred over parenteral nutrition, 
and the prone position is not a contraindication to 
enteral feeding61,96.
Research recommendations
1. Determine the role of antivirals, steroids and systemic 
anticoagulants in the development and progression 
of AKI.
2. Determine the pharmacokinetics of antivirals and 
immunomodulatory drugs during different phases 
of AKI and progression to acute kidney disease 
(deteriorating, maintenance and recovery) and with 
different types of RRT.
3. Explore the nutritional status and energy expendi-
ture of patients with COVID-19 AKI, and determine 
strategies for their optimal nutritional management 
according to RRT status.
Renal replacement therapy
Patient- specific considerations
If adequate RRT resources are available, are there 
patient- specific considerations with respect to vascular 
access, timing, modality, or dose of acute RRT for patients 
with COVID-19 AKI?
Recommendations. 
1. We recommend that the use of ultrasound for insertion 
of vascular access and RRT dose delivery remain based 
on KDIGO AKI guidelines (evidence level: 1A).
2. Timing of RRT initiation, vascular access site and 
modality of acute RRT should be based on patient 
High risk AKI stage 1 AKI stage 2 AKI stage 3
Standard of care to prevent and manage multiorgan failure
Individualize fluid management, avoid saline unless specific indication
Consider dynamic haemodynamic monitoring
Monitor serum creatinine and urine output
Correct hypoglycaemia
Consider alternatives to radiocontrast if possible without delaying urgent imaging
Avoid nephrotoxic agents when possible
Consider AKI risk in selecting ventilator strategies
Diagnostic workup
Consider altered pharmacokinetics
Consider renal replacement therapy
Avoid subclavian access
Direct viral effect:
Coronavirus 
kidney infection
Indirect effects:
• Hypervolaemia
• Injury to the lungs
• Systemic inflammation 
Clinical management effects:
• Nephrotoxins
• Hypervolaemia
• Lung–kidney crosstalk 
• Superinfection
• Rhabdomyolysis
• Formation of thrombi
Fig. 2 | Stage-based management of CoVID-19 AKI. The pathogenesis of acute kidney injury (AKI) in patients with 
COVID-19 (COVID-19 AKI) likely involves direct viral effects, indirect effects and sequelae from disease management. 
There is no specific evidence to suggest that COVID-19 AKI should be managed differently from other causes of AKI in 
critically ill patients; however, the possible underlying disease mechanisms should be taken into account when considering 
approaches to the management of COVID-19 AKI throughout the disease course. Adapted with permission from rEF.61, 
Elsevier, and Acute Disease Quality Initiative 25, www.ADQI.org, CC BY 2.0 (https://creativecommons.org/licenses/by/2.0/).
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needs, local expertise and the availability of staff and 
equipment (TABlEs 3,4) (not graded). 
3. As COVID-19 often induces a hypercoagulable state, if 
using CRRT, we suggest use of continuous veno- venous 
haemodialysis or continuous veno- venous haemodia-
filtration to decrease filtration fraction and reduce the 
risk of circuit clotting (evidence level: 2C).
Rationale. A number of clinical trials and meta- analyses 
of RRT initiation strategies in critically ill patients have 
demonstrated no difference in mortality or renal recov-
ery associated with initiation of RRT in the absence of 
emergent indications97–100. The decision to initiate acute 
RRT in patients with COVID-19 AKI should therefore 
be individualized, and clinical context should be consid-
ered (e.g. initiation of RRT for volume management in 
patients with severe hypoxaemia) and not based solely 
on AKI stage or degree of renal function61,101. Selection 
of RRT modality will depend on local availability and 
resources, as no clear benefit with any specific RRT 
modality is known. However, continuous therapies 
may be better tolerated in patients with haemodynamic 
instability and facilitate improved volume and nutrition 
management, which are important in the management 
of patients with COVID-19 (rEF.61).
The dose of RRT should be based on KDIGO recom-
mendations and be adjusted in response to changes in 
clinical, physiological and/or metabolic status61,102,103. 
In patients with COVID-19, coagulopathy resulting in 
circuit clotting can interrupt prolonged RRT sessions 
and substantially affect the dose delivered. This com-
plication of COVID-19 may require the RRT prescrip-
tion to be adjusted104,105. If CRRT is used, a reduction 
in the filtration fraction may reduce circuit clotting106. 
Acute peritoneal dialysis (PD) might also be an effec-
tive option for patients who are unable to receive 
anticoagulants107–110.
The choice between jugular or femoral sites for vas-
cular access in patients with COVID-19 is based on the 
experience and preference of the clinician. For patients 
with a body mass index >28 kg/m2, internal jugular (IJ) 
sites have lowest infection rates111,112. Higher rates of vas-
cular access dysfunction have been observed with the 
use of the left IJ, compared with the right IJ or femoral 
sites, but many cases of left IJ access dysfunction proba-
bly result from the inadequate depth of the catheter tip at 
Table 3 | recommendations for rrT use in patients with CoVID-19 AKI
Considerations rrT management for CoVID-19 AKI rrT management during a period of increased rrT demand 
(rrT surge)
RRT indications Consider acute RRT when metabolic and fluid demands 
exceed total kidney capacity
Consider the broader clinical context and conditions 
that can be modified by RRT rather than BUN or 
creatinine alone when determining the need for  
RRT initiation
Consider a judicious and safe use of intravenous bicarbonate, 
potassium binding resins and diuretics to forestall RRT initiation
RRT should be initiated immediately if there is a failure  
of conservative measures or clinical deterioration
Modality Selection of modality should be based on patient needs, 
local expertise and availability of staff and equipment
Prolonged modes of RRT (CRRT, PIRRT, SLED or PD) should 
be considered for haemodynamically unstable patients, 
those with marked fluid overload, or in whom shifts in fluid 
balance are poorly tolerated
CVVHD or CVVHDF modality and minimizing post- filter 
replacement fluid in patients who are on CRRT will 
decrease the filtration fraction and reduce the risk of 
circuit clotting
Modality choice may be affected by the supply of disposable 
materials (dialyzer filters, machine tubing sets, dialysis solutions 
and anticoagulation medications), machine availability and the 
availability of appropriately trained staff to operate machines and 
safely deliver RRT
Advantages of PIRRT or IHD may include a reduced need for 
anticoagulation and shorter duration of therapy session, thereby 
optimizing machine and human resources to increase the number  
of patients who can receive RRT per day
In the event of limited machine availability, consider shorter 
durations of IHD or use of CRRT machines for PIRRT (i.e. in a 
shift- based approach)
If IHD or CRRT machine availability is limited, consider use of acute 
PD, as PD requires relatively less equipment, infrastructure and 
resources without a need for RRT- related anticoagulation
RRT dose CRRT: delivered effluent flow rate of 20–25 ml/kg/h 
(prescribed dose of 25–30 ml/kg/h)
IHD or PIRRT: minimum three times per week (alternate days)
Interruption of prolonged RRT modality (CRRT, PIRRT or 
SLED) sessions due to circuit clotting can have a substantial 
impact on the actual delivered dose and the dose may 
therefore need to be adjusted to account for this disruption
Consider using lower than usual flow rates once metabolic control 
has been achieved if concerns exist about the availability of 
consumables (e.g. filters or dialysate solutions)
If shorter durations of IHD or CRRT machines for PIRRT are prescribed 
or required, we recommend that appropriate adjustments are 
made in fluid removal targets and RRT dose to achieve appropriate 
fluid balance targets and metabolic control (e.g. an increase in 
effluent dose)
Vascular access Right IJ is the preferred site
Prone position, obesity and hypercoagulability may affect 
vascular access performance
No anticipated differences in preferred vascular access sites during 
an RRT surge
Develop local expertise and teams for acute PD catheter insertion 
(ICU bedside versus operating room)
AKI, acute kidney injury; BUN, blood urea nitrogen; CRRT, continuous renal replacement therapy; CVVHD, continuous veno- venous haemodialysis; CVVHDF, 
continuous veno- venous haemodiafiltration; ICU, intensive care unit; IHD, intermittent haemodialysis; IJ, internal jugular; PD, peritoneal dialysis; PIRRT, prolonged 
intermittent renal replacement therapy; RRT, renal replacement therapy; SLED, slow- low efficiency dialysis.
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the left IJ site61,111,113. The use of ultrasound for the place-
ment of IJ vascular access increases the likelihood of suc-
cessful catheter placement, with reduced complications 
and time required for the procedure.
Anticoagulation strategies
What is the optimal anticoagulation strategy for acute 
RRT in COVID-19 AKI?
Recommendations. 
1. We recommend that patients with COVID-19 AKI 
receive anticoagulation agents during extracorporeal 
RRT (evidence level: 1C).
2. We suggest RRT that circuit performance be closely 
monitored to ensure maximal circuit patency as the 
initial anticoagulation strategy may not be effective in 
all patients; we also recommend that each centre estab-
lish a stepwise escalation and/or alternative plans for 
RRT anticoagulation (evidence level: 2C).
Rationale. KDIGO recommends the use of anticoag-
ulation for CRRT unless it is contraindicated or the 
patient is already receiving systemic anticoagulation61. 
COVID-19 induces a hypercoagulable state in many 
patients, which can result in premature extra- corporeal 
RRT circuit failure114–117. Additionally, an anonymized 
survey of the ADQI faculty involved in this Consensus 
Statement revealed that 64% of respondents identified a 
high rate of circuit loss or clotting during RRT in patients 
with COVID-19 as an issue requiring “major revision 
of treatment and anticoagulation protocols” and/or 
“significantly compromising patient care even after 
optimization of anticoagulation,” compared with only 3 
of 25 (12%) who reported no differences in frequency of 
RRT circuit loss compared with that observed in patients 
without COVID-19.
Owing to the hypercoagulable state of patients with 
COVID-19, therapeutic, titratable, pharmacological 
anticoagulation has been used more often during RRT 
to reduce the risk of filter clotting. However, no studies 
are available to guide the selection of an anticoagulation 
strategy. Several anticoagulation strategies can be used 
with a broad array of extra- corporeal RRT therapies 
in patients with COVID-19, including regional citrate 
anticoagulation in CRRT, therapeutic, titratable antico-
agulation with unfractionated or low- molecular- weight 
heparins, direct thrombin inhibitors and combinations 
of these approaches. Change in RRT modality to inter-
mittent haemodialysis (IHD), prolonged intermittent 
RRT (PIRRT), or acute PD should be considered in 
Table 4 | rrT modality options for patients with CoVID-19 AKI
Modality Advantages in CoVID-19 AKI Disadvantages in CoVID-19 AKI
IHD Widely available
Allows treatment of several patients with 
the same machine in a given day
Higher blood flow may reduce risk of 
clotting
Less effective in reaching daily fluid balance goals
Can lead to or exacerbate haemodynamic instability
Usually requires a dedicated HD nurse or other staff in 
addition to an ICU nurse (increasing staff exposure to the 
isolation environment)
PIRRT: IHD 
or CRRT
Less likely than other modalities to 
exacerbate haemodynamic instability
Allows treatment of several patients with 
the same machine in a given day
Option for higher blood flow, which may 
reduce risk of circuit clotting
Not as widely available as other modalities (i.e. hospital 
protocols are not widely established)
Given the procoagulant nature of COVID-19, systemic 
anticoagulation may be necessary
Challenges and uncertainty of drug dosing, especially for 
antimicrobial and/or COVID-19 therapeutics
CRRT Achieves steady- state control of small 
solutes and acid- base status
Least likely to exacerbate haemodynamic 
instability
Easy to achieve net negative fluid balance 
and achieve fluid balance targets with 
greater haemodynamic stability
Can often be performed by the patient’s 
bedside in the ICU, limiting staff contact 
with the isolation environment
Not as widely available as other modalities outside of 
resource- rich settings or tertiary centres
Requires one machine per patient per day
Requires ICU settings and may require 1:1 nursing ratio 
depending on institutional policies
Given the procoagulable nature of COVID-19, 
anticoagulation is recommended and may require systemic 
therapeutic anticoagulation
Increased frequency circuit clotting may lead to a lower 
delivered dose, inability to achieve fluid balance targets  
and increased resource utilization (which may have supply 
chain impacts)
PD Widely available
No circuit clotting concerns
No venous access required
Less likely to exacerbate haemodynamic 
instability
Less nursing exposure with the use of 
automated cycler
May be more challenging in patients in prone positions
Risk of peri- catheter leaks
Protocols and policies for acute PD are not available at all 
sites. Requires technical expertise to place catheters
May require rapid implementation of training regimen for 
renal nurses and clinicians
AKI, acute kidney injury; CRRT, continuous renal replacement therapy; CVVHD, continuous veno- venous haemodialysis; CVVHDF, 
continuous veno- venous haemodiafiltration; ICU, intensive care unit; IHD, intermittent haemodialysis; PIRRT, prolonged 
intermittent renal replacement therapy; PD, peritoneal dialysis; SLED, slow- low efficiency dialysis; RRT, renal replacement therapy.
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patients with persistent circuit clotting during CRRT 
despite anticoagulation.
Unplanned interruptions due to circuit failures with 
CRRT, PIRRT or IHD will increase the consumption 
rate of disposable supplies, increase the risk of exposure 
of nursing and other staff to infection, increase the risks of 
inadequate electrolyte, acid- base, fluid balance control, 
and influence medication pharmacokinetics. Therefore, 
it is important to strive to maximize the utility of any RRT 
circuit in order to conserve supplies, as supply chains can 
become challenged and limited in the context of a pan-
demic. During an increase in RRT demand, monitoring 
CRRT circuit lifespan is of paramount importance at both 
the individual and the organizational level. If poor per-
formance is noted, we suggest prompt implementation of 
a stepwise approach to anticoagulation to minimize the 
supply consumption and conserve resources.
Surge planning
What are the key considerations when planning for a 
sudden surge in acute RRT demand?
Recommendations. 
1. A coordinated response to an increase in RRT demand 
and/or supply chain failure at an organizational, 
regional and national level is needed (not graded).
2. Consider adjustments to RRT modality, indications, 
anticoagulation and dose as part of a local response 
to an imbalance in supply and/or demand to conserve 
scarce resources and deliver effective therapy to the 
greatest number of patients (not graded).
Rationale. In any situation with a rapid increase in ICU 
demand, it is possible that the provision of RRT may be 
limited. To prepare for such situations, we recommend 
that health systems create, maintain and periodically 
update an RRT ‘surge plan’ (Fig. 3). A sudden spike in 
cases of COVID-19 or future entities might cause unfore-
seen shortages of RRT devices and/or RRT disposables 
and fluids118. Additionally, supply chain security may be 
compromised, further augmenting local shortages119,120. 
As part of a local surge response, use of a wider variety 
of acute RRT modalities (CRRT, PIRRT, IHD and acute 
PD) may be needed to maximize the number of patients 
who can receive RRT. Several institutions reported hav-
ing to implement acute PD during the initial surge in 
COVID-19 cases108,110,121–124. In the preparatory and early 
response phase, hospitals and regional health systems 
should maintain an ongoing inventory of available RRT 
devices, disposable RRT equipment, and RRT fluids, and 
make projections of demand to optimize resource uti-
lization. In addition, workforce planning and response 
Pandemic or disaster
Goals Local responses Regional or national responses
Policies, training
and resources to
deal with RRT surge
• Develop local RRT surge plan
• Maintain inventory of RRT devices
• Widen staff RRT cross-training
• Systems for co-ordination of RRT
emergency response
• Consider RRT stockpiles
• Secure supply chains
• Encourage local planning
• Industry response plan
Maintain availability
of RRT to all requiring it
• Centralized resource-
allocation systems
• Publicize clinical guidelines
• Develop networks for 
inter-centre patient transfer
• Enable knowledge sharing
Potential crisis in RRT provision
Increase
in RRT 
demand
Reduced
RRT
capacity
• Substantially increased local RRT 
demand
• Increased disposable consumption 
due to illness-specific effects
• Increased disposable consumption 
due to effects of surge response
• Increase in regional, national or 
worldwide RRT demand
• Interruption of disposable manufacture 
and insecure supply chains
• Lack of experienced staff to meet 
increased workload
• Review availability of RRT capacity
• Optimize non-dialytic AKI 
management
• Reinforce RRT guidelines
• Review preferred RRT presciption
• Consider alternative RRT modes
Maintain availability
of RRT to all requiring it
• Centralized resource-
allocation systems
• Publicize clinical guidelines
• Develop networks for 
inter-centre patient transfer
• Enable knowledge sharing
• Review availability of RRT capacity
• Optimize non-dialytic AKI 
management
• Reinforce RRT guidelines
• Review preferred RRT presciption
• Consider alternative RRT modes
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Fig. 3 | Step-wise plan to prepare for a surge in rrT demand during a pandemic or disaster. A sudden spike in  
cases of COVID-19 disease might cause unforeseen shortages of renal replacement therapy (RRT) devices and/or RRT 
disposables and fluids. In addition, supply chain security might be compromised, further contributing to local shortages. 
As part of a local surge response, use of a wider variety of acute RRT modalities may be needed to maximize the number  
of patients who can receive RRT. Adapted from Acute Disease Quality Initiative 25, www.ADQI.org, CC BY 2.0 (https://
creativecommons.org/licenses/by/2.0/).
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to a surge in COVID-19 cases should project the need 
for trained RRT nursing support and ensure that the 
relevant human resources are available125.
Excessive consumption of RRT disposables due both 
to increased demand and poor circuit performance has 
the potential to cause critical shortages, compromis-
ing the ability to deliver RRT to all who might benefit. 
Aggressive medical management of electrolyte and 
acid- base disturbances or fluid overload might negate 
the need for RRT or forestall RRT initiation, thereby ena-
bling improved allocation of finite RRT resources126,127. 
Also, depending on the type of shortages anticipated 
(machine or disposables), strategies such as lowering 
blood flows to reduce citrate consumption, moderating 
the RRT intensity to conserve fluids or running acceler-
ated RRT at higher clearance to treat more patients per 
machine could form part of a local response128. Finally, 
earlier transition to IHD with dialysate generated online 
or acute PD could be valuable options in centres with 
appropriate resources and expertise107,108,110.
A large surge in COVID-19 cases may make deliv-
ery of treatment to all who might benefit impossible, 
despite appropriate planning. Detailed discussion of 
the ethical and legal considerations in these circum-
stances is, however, outside the scope of this consensus 
statement.
Research recommendations
1. Develop a registry of patients with severe COVID-19 
AKI to research whether variations in clinical prac-
tice relating to differences in RRT use and circuit 
performance affect clinical outcomes.
2. Given the specific issues with circuit loss associated 
with RRT for COVID-19 AKI, we recommend the 
planning and initiation of prospective RCTs to exam-
ine different anticoagulation strategies for CRRT 
and PIRRT.
3. We recommend implementation of a programme of 
operational research, including supply chain man-
agement, to examine the local, regional and national 
responses to the RRT supply–demand imbalance 
during the COVID-19 pandemic and to develop 
evidence- based strategies for future emergencies.
4. We recommend that in observational studies, the 
consequences of a delayed RRT and use of alter-
native, non- standard modalities in response to the 
lack of RRT capacity be investigated to determine to 
what extent the policies developed and implemented 
during the pandemic were safe and effective.
Extracorporeal blood purification
Biological rationale
What is the potential biological rationale for using 
(non- renal) EBP in critically ill patients with COVID-19?
1. Inf lammatory cytokines, DAMPs ,  pathogen- 
associated molecular patterns (PAMPs), including 
endotoxins and SARS- CoV-2 particles, potentially 
contribute to the development of multiple organ failure 
and mortality in critically ill patients with COVID-19.
2. EBP techniques have been shown to remove cytokines, 
DAMPs and PAMPs, including endotoxins and 
circulating viral particles.
Rationale. EBP has been proposed as a possible adju-
vant therapy for critically ill patients with COVID-19 
on the basis that removal of circulating immunomodu-
latory mediators might prevent organ damage or miti-
gate organ failure in patients with COVID-19 (rEFs129,130) 
(Fig. 4). Multiple organ failure in COVID-19 might result 
from the propagation of an uncontrolled host immune 
response involving the release of various immune medi-
ators such as cytokines, DAMPs and PAMPs35,65,131,132. 
In sepsis, this type of uncontrolled immune response is 
characterized by hyperinflammation, cytokine release, 
endothelial dysfunction and hypercoagulability66,133–135. 
However, as discussed earlier, cytokine activation is not 
typically as robust in COVID-19 as it is in SARS and 
MERS43–45, or in patients treated with chimeric anti-
gen receptor T cell therapy or with bacterial sepsis46,47. 
Moreover, the benefits and adverse effects of EBP in 
Pathogen- associated 
molecular patterns
(PAMPs). Molecules released 
from pathogens (especially 
bacteria) that can precipitate 
inflammation often signalling 
through specific receptors such 
as Toll- like receptors. Common 
PAMPs include components of 
the bacterial cell wall (e.g. 
endotoxin, lipoteichoic acid).
• COVID-19 pneumonia
• Hypercoagulability or 
hyperviscosity
Prevention or mitigation
of organ damage
• Circulating mediators 
(cytokines, DAMPs)
• SARS-CoV-2 virus?
• HP for cytokine removal
• TPE
• HP for virus removal?
Prevention of progression
of organ failure
• Circulating mediators 
(cytokines, DAMPs, PAMPs)
• Myoglobin
• Fluid overload
• Uraemic solute retention
• Endotheliitis
• Activation of 
endothelial cells
• IL-6
• TNF
• DAMPs
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• ARDS
• Myocardial infarction or 
myocarditis
• AKI
• Sepsis or septic shock due 
to super-imposed infection
• Hypercoagulability or 
hyperviscosity
SARS-CoV-2 Neutrophil Macrophage
PAMPs 
(e.g. endotoxin)
• Uraemic toxins
• Myoglobin
H+
H+
H+
• HP for cytokine or 
endotoxin removal
• RRT with adsorptive and 
MCO or HCO membranes
• TPE
Fig. 4 | potential extracorporeal blood purification treatment options based on 
underlying CoVID-19 pathophysiology. Extracorporeal blood purification (EBP) has 
been proposed as a possible adjuvant therapy for critically ill patients with COVID-19 on 
the basis that removal of circulating immunomodulatory factors, that might contribute 
to disease processes and/or the development of multiple organ failure, might improve 
outcomes. Of note, the efficacy of EBP in patients with COVID-19 and/or COVID-19 AKI 
has not been tested, and all therapeutic options must therefore be tested in clinical trials 
in the context of COVID-19. EBP therapies should be considered complementary to 
pharmacological support. EBP therapies may also be considered in sequence or as separate 
entities according to current evidence or pathophysiological rationale, as changes in 
pathophysiology over the disease course might indicate different treatment approaches. 
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; COVID-19, coronavirus 
disease 2019; DAMPs, damage- associated molecular patterns; HCO, high cut- off; HP, 
haemoperfusion; MCO, medium cut- off; PAMPs, pathogen- associated molecular patterns; 
RRT, renal replacement therapy; TPE, therapeutic plasma exchange. Adapted from Acute 
Disease Quality Initiative 25, www.ADQI.org, CC BY 2.0 (https://creativecommons.org/
licenses/by/2.0/).
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patients with COVID-19 have not been formally studied. 
Thus, we suggest that patients for whom EBP is being 
considered are selected carefully.
EBP techniques
Which EBP techniques can potentially be used to remove 
circulating molecules implicated in the pathophysiology of 
COVID-19? 
1. Haemoperfusion techniques can remove inflam-
matory molecules, DAMPs and PAMPs, including 
SARS- CoV-2 particles.
2. Therapeutic plasma exchange (TPE) can remove 
inflammatory mediators and proteins associated with 
hypercoagulability.
3. CRRT with surface- modified AN69 or polymethyl-
methacrylate membranes can remove target molecules 
by adsorption, whereas CRRT with medium cut- off or 
high cut- off membranes can remove target molecules 
by diffusion or convection.
Rationale. Many health- care agencies have authorized 
emergency use of various EBP techniques to remove 
molecules that are potentially causative of the immuno- 
inflammatory response in critically ill patients with 
COVID-19. However, these EBP techniques have not 
yet been formally studied in this patient population 
(Supplementary Table 2). Haemoperfusion sorbents 
might target the removal of virus particles, cytokines and 
DAMPs in patients with high endotoxin levels136–140. In a 
small RCT of patients with septic shock (EUPHAS), the 
use of haemoperfusion was associated with improved 
organ function and a survival benefit141; however, a larger 
RCT (EUPHRATES) failed to confirm these findings136. 
A post hoc analysis of the EUPHRATES trial demon-
strated possible therapeutic survival effect in a subgroup 
of patients with endotoxin activity in a specific range140. 
TPE has been shown in RCTs to improve haemody-
namics, induce favourable changes in cytokine profile 
and improve survival in patients with septic shock142,143. 
Removal of inflammatory cytokines with TPE could, in 
theory, confer some benefit in patients with COVID-19 
with hyperinflammation and hypercoagulability144. 
CRRT with medium cut- off, high cut- off or adsorptive 
membranes can remove cytokines or myoglobin and 
potentially prevent myoglobin- induced AKI145,146.
Criteria for EBP use
What are possible biological and/or clinical criteria for ini-
tiating, monitoring, and discontinuing EBP in critically ill 
patients with COVID-19?
Recommendations. 
1. No consensus exists on the use or thresholds of specific 
biological and clinical criteria for initiating, monitor-
ing or discontinuing EBP in critically ill patients with 
COVID-19 (not graded).
Rationale. If used, EBP therapies should be selected on 
the basis of the pathophysiology they are designed to 
target. Numerous clinical criteria, including body tem-
perature, haemodynamic status, need for vasopressor 
support, respiratory status and oxygenation, multiorgan 
failure score, cardiac and kidney function, as well as 
laboratory parameters such as lymphocyte counts, con-
centration of cytokines, ferritin, lactate dehydrogenase, 
D- dimers, monocytic expression of HLA, myoglobin, 
troponin, C- reactive protein, endotoxin activity, pro-
calcitonin and culture results may be useful in evalu-
ating the suitability of a patient for initiation of EBP. 
However, the precise indication for EBP in patients with 
COVID-19 remains to be determined. EBP for endo-
toxin removal has been generally applied for 48 consecu-
tive hours and for 72 h for cytokine removal in studies of 
septic patients and in ongoing COVID-19 trials140,146–149. 
However, there are limited data regarding the timing 
of initiation or duration of use of these therapies, and 
further studies are needed.
Research recommendations
1. Future trials should measure the ability of EBP to 
remove target molecules, including assessment of their 
kinetics, to confirm the pathophysiological rationale 
for use of EBP in critically ill patients with COVID-19.
2. Future trials should assess whether use of EBP is asso-
ciated with improved short- term outcomes, including 
prevention and mitigation of organ failure.
3. Future trials should assess whether combined or 
sequential EBP techniques can reach meaningful 
biological and/or clinical end points.
4. The ability of haemoperfusion to prevent or mit-
igate organ failure by removal of the SARS- CoV-2 
virus in patients with detected viraemia should be 
investigated.
5. Future studies should validate the biological and clini-
cal parameters that identify individuals who are likely 
to benefit and respond to EBP, as well as parameters 
for monitoring and discontinuing treatments.
6. Future studies should evaluate TPE as an alternative 
for reducing hypercoagulability, hyperviscosity, and 
hyperinflammation in patients with COVID-19, 
and also assess the negative consequences of remov-
ing potentially beneficial molecules (e.g. removal of 
protective SARS- CoV-2 antibodies).
7. Future studies should assess the removal of drugs and 
nutrients during EBP and any resulting potentially 
negative consequences on patient outcomes.
Conclusions
Kidney involvement following SARS- CoV-2 infection is 
more common than initially thought and is associated 
with morbidity and mortality. The pathophysiology of 
COVID-19 AKI is probably multifactorial — in line 
with the pathophysiology of other forms of AKI. Rates 
of COVID-19 AKI vary considerably between studies 
and regions, although available evidence suggests an 
incidence of over 20% in hospitalized patients. Many 
features, such as risk factors, likely mechanisms and 
outcomes, are shared between COVID-19 AKI and AKI 
arising from non- viral causes encountered in the ICU. 
Thus, many of the treatment recommendations, as well 
as preventative measures described in this Consensus 
Statement, are common to both. Considerations for RRT 
are also similar with the caveat that more aggressive anti-
coagulant regimes may be needed and that treatment 
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may need to be adjusted to conserve resources in the 
context of a surge in COVID-19 cases. Given the poten-
tial contribution of systemic inflammation to multiorgan 
failure in COVID-19, the use of extracorporeal therapies 
may also be considered. Of note, new data on COVID-19 
AKI are continually being published and these recom-
mendations may therefore require modifications as new 
results become available.
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